The data showcased in most cancer systems suggest the increased association of HSP70 and HSP90 with HOP is pro-proliferation; therefore, targeting a switch in preference to CHIP-containing chaperone complexes may have anticancer benefits, highlighting the role for balance between CHIP-versusHOP-containing chaperone complexes. The gene discussed is HSP90AA1; the disease is cancer.